• 글쓰기
• 목록

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medication isn't effective. The individual approach to treatment could be the solution.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and uncover distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

depression treatment london is a leading cause of mental illness in the world.1 Yet, only half of those suffering from the condition receive treatment. To improve outcomes, healthcare professionals must be able identify and treat patients most likely to respond to specific treatments.

A customized depression treatment plan can aid. Utilizing sensors for mobile phones and an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new alternative ways to treat depression to determine which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to identify biological and behavior predictors of response.

The majority of research conducted to so far has focused on clinical and sociodemographic characteristics. These include demographics like age, gender, and education, as well as clinical characteristics such as symptom severity and comorbidities as well as biological markers.

A few studies have utilized longitudinal data to predict mood of individuals. Many studies do not take into account the fact that moods can differ significantly between individuals. Therefore, it is important to develop methods that allow for the determination and quantification of the individual differences in mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can detect various patterns of behavior and emotion that vary between individuals.

The team also developed a machine learning algorithm to create dynamic predictors for the mood of each person's depression. The algorithm blends the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated scale for assessing severity of symptom. The correlation was low, however (Pearson r = 0,08, P-value adjusted for BH = 3.55 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is a leading cause of disability in the world1, but it is often not properly diagnosed and treated. In addition, a lack of effective treatments and stigma associated with depressive disorders stop many people from seeking help.

To facilitate personalized treatment to improve treatment, identifying the predictors of symptoms is important. Current prediction methods rely heavily on clinical interviews, which are not reliable and only identify a handful of characteristics that are associated with depression.

Using machine learning to integrate continuous digital behavioral phenotypes captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory CAT-DI) along with other indicators of severity of symptoms can improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a variety of distinct behaviors and patterns that are difficult to record through interviews.

The study involved University of California Los Angeles (UCLA) students with moderate depression treatment to severe depressive symptoms. participating in the Screening and Treatment for Anxiety and Postpartum Depression Treatment (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were referred to online support or clinical care according to the severity of their depression. Participants who scored a high on the CAT-DI scale of 35 or 65 were assigned online support with the help of a peer coach. those who scored 75 were sent to clinics in-person for psychotherapy.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial characteristics. The questions included education, age, sex and gender as well as financial status, marital status and whether they were divorced or not, the frequency of suicidal ideas, intent or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression symptoms on a scale ranging from 100 to. The CAT DI assessment was carried out every two weeks for participants who received online support, and weekly for those who received in-person care.

Predictors of Treatment Reaction

The development of a personalized depression treatment is currently a major research area and many studies aim at identifying predictors that enable clinicians to determine the most effective medications for each individual. Particularly, pharmacogenetics is able to identify genetic variants that determine how the body metabolizes antidepressants. This enables doctors to choose the medications that are most likely to work best treatment for anxiety and depression for each patient, while minimizing the time and effort involved in trial-and-error treatments and eliminating any side effects that could otherwise slow the progress of the patient.

Another promising approach is building models of prediction using a variety of data sources, such as data from clinical studies and neural imaging data. These models can be used to determine the variables that are most likely to predict a specific outcome, like whether a medication will help with symptoms or mood. These models can be used to predict the response of a patient to a treatment, allowing doctors to maximize the effectiveness of their treatment.

A new type of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and increase predictive accuracy. These models have been demonstrated to be effective in predicting the outcome of treatment like the response to antidepressants. These models are getting more popular in psychiatry and it is likely that they will become the norm for the future of clinical practice.

Research into the underlying causes of depression continues, as do ML-based predictive models. Recent research suggests that depression is related to dysfunctions in specific neural networks. This theory suggests that individualized depression treatment will be based on targeted therapies that target these circuits in order to restore normal function.

One method to achieve this is to use internet-based interventions which can offer an individualized and tailored experience for patients. One study found that an internet-based program helped improve symptoms and improved quality of life for MDD patients. A controlled, randomized study of a customized treatment for depression found that a significant number of participants experienced sustained improvement as well as fewer side effects.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and determining which antidepressant medication will have no or minimal negative side effects. Many patients take a trial-and-error approach, using several medications prescribed until they find one that is safe and effective. Pharmacogenetics is an exciting new method for an efficient and specific method of selecting antidepressant therapies.

A variety of predictors are available to determine which antidepressant is best to prescribe, including genetic variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and co-morbidities. However finding the most reliable and valid predictive factors for a specific treatment will probably require randomized controlled trials of much larger samples than those normally enrolled in clinical trials. This is due to the fact that it can be more difficult to detect interactions or moderators in trials that contain only one episode per participant rather than multiple episodes over a period of time.

In addition the prediction of a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's subjective perception of the effectiveness and tolerability. Currently, only a few easily identifiable sociodemographic variables and clinical variables seem to be consistently associated with response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

There are many challenges to overcome in the use of pharmacogenetics to treat pregnancy depression treatment. First, it is important to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as an understanding of an accurate indicator of the response to treatment. Additionally, ethical issues like privacy and the responsible use of personal genetic information must be considered carefully. Pharmacogenetics can be able to, over the long term, reduce stigma surrounding mental health treatment and improve the quality of treatment. As with all psychiatric approaches, it is important to carefully consider and implement the plan. For now, the best course of action is to offer patients a variety of effective depression medication options and encourage them to talk with their physicians about their experiences and concerns.